AFT Pharmaceuticals identifies multi-billion-dollar market potential with expanding portfolio

• Set to extend two-decade 17% revenue growth record
• Eight patented projects and 24 off patent injectables created
• Strengthening business hubs in Australia, NZ, Singapore, Hong Kong, USA, Canada and UK

AFT Pharmaceuticals (ASX:AFP) has unveiled new growth opportunities in its research and development portfolio and business hubs.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The company told shareholders it is set to extend the company’s two-decade 17% (CAGR) revenue growth record.

MD, Dr Hartley Atkinson, said the portfolio — which now extends to eight patented projects, 24 off patent injectables and a range of other projects in the early stages of commercialisation – offers the company multi-billion-dollar addressable `markets.

He told shareholders the company is also developing and strengthening its business hubs in Australia, New Zealand, Singapore, Hong Kong, USA, Canada and United Kingdom which for selected parts of the R&D portfolio would then allow AFT to cover up to 50% of the global market directly.

“The strength, depth and potential of our development portfolio, our record of successfully developing and commercialising innovative medicines, and the returns they have delivered for shareholders to date are a story we are keen to outline more fully,” Dr Atkinson said.

“It is for this reason we are today taking investors on a deeper dive into the portfolio so they can better understand the excitement we have for the significant current and future upside it offers us.”

In a gathering in Aukland, AFT highlighted how research and development projects have already contributed significant shareholder value.

Notably, the company explained how the intravenous form of its patented Maxigesic pain relief medicine was developed. It contrasts this with multi-million dollar returns on that investment to date including:

• NZ$21 million from licensing the intellectual property to markets where it does not operate.

• NZ$5.5 million of royalties on sales by those licensees; and

• multiple millions in margin from sales in the many markets.

“AFT’s long-standing and unbroken record of growth is founded on a highly successful record of identifying unmet clinical needs and then in licensing or developing the right medicines to meet that need. We are now successfully taking these products to multiple markets around the world,” Dr Atkinson said.

“Few pharmaceutical companies in New Zealand or Australia straddle both the development of intellectual property and the commercialisation of speciality medicines. Fewer still fund this growth largely from internally generated cashflows. AFT does both. We are proud of our record, and excited by the growing potential.”

AFP was steady at $3.57 with a Mkt cap of $374.4M before markets opened.

Join the discussion: See what HotCopper users are saying about AFT Pharmaceuticals and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.